Kemeriz, FundaAcar, Emine MügeOrdu, Melike2020-09-222020-09-2220201396-0296Article number e13542https:/dx.doi.org/10.1111/dth.13542https://hdl.handle.net/20.500.12451/7677*Kemeriz, Funda ( Aksaray, Yazar ) *Ordu, Melike ( Aksaray, Yazar )Dear Editor Omalizumab is a humanized monoclonal antibody against human immunoglobulin E that is mainly indicated in asthma, allergic rhinitis, chronic spontaneous urticaria and is being increasingly used for other dermatological diseases, including atopic dermatitis, mastocytosis, hyper-IgE syndrome, and bullous pemphigoid.1,2 Rare cutaneous side effects, such as itching, skin rash, urticaria, and photosensitivity, have been reported to be associated with omalizumab use.eninfo:eu-repo/semantics/embargoedAccessAntihistaminic AgentOmalizumabSteroidLetter334--10.1111/dth.1354232385946Q1WOS:000535125400001Q3